KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioEBIT MarginEBITDA MarginEBT MarginEnterprise ValueFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on Invested CapitalReturn on SalesTimes Interest Earned

BioNTech SE (BNTX) Gross Margin (2018 - 2025)

Historic Gross Margin for BioNTech SE (BNTX) over the last 8 years, with Q3 2025 value amounting to 90.24%.

  • BioNTech SE's Gross Margin rose 46100.0% to 90.24% in Q3 2025 from the same period last year, while for Sep 2025 it was 82.79%, marking a year-over-year decrease of 15200.0%. This contributed to the annual value of 80.32% for FY2024, which is 39700.0% down from last year.
  • Per BioNTech SE's latest filing, its Gross Margin stood at 90.24% for Q3 2025, which was up 46100.0% from 70.71% recorded in Q2 2025.
  • In the past 5 years, BioNTech SE's Gross Margin ranged from a high of 95.71% in Q4 2022 and a low of 2.86% during Q2 2023
  • For the 5-year period, BioNTech SE's Gross Margin averaged around 75.72%, with its median value being 80.1% (2021).
  • Its Gross Margin has fluctuated over the past 5 years, first tumbled by -732200bps in 2023, then soared by 506700bps in 2024.
  • Over the past 5 years, BioNTech SE's Gross Margin (Quarter) stood at 89.46% in 2021, then grew by 7bps to 95.71% in 2022, then dropped by -8bps to 87.89% in 2023, then decreased by -10bps to 79.54% in 2024, then grew by 13bps to 90.24% in 2025.
  • Its last three reported values are 90.24% in Q3 2025, 70.71% for Q2 2025, and 54.16% during Q1 2025.